Page 62 - Read Online

Page 12 of 14 Stenina-Adognravi et al. Vessel Plus 2018;2:30 I http://dx.doi.org/10.20517/2574-1209.2018.40

cancer risk. Nutr Cancer 2011;63:860-72.
98. Nagle CM, Olsen CM, Ibiebele TI, Spurdle AB, Webb PM, et al. Glycemic index, glycemic load and endometrial cancer risk: results
from the Australian national endometrial cancer study and an updated systematic review and meta-analysis. Eur J Nutr 2013;52:705-15.
99. Larsson SC, Giovannucci EL, Wolk A. Prospective study of glycemic load, glycemic index, and carbohydrate intake in relation to risk
of biliary tract cancer. Am J Gastroenterol 2016;111:891-6.
100. Sieri S, Krogh V, Agnoli C, Ricceri F, Palli D, et al. Dietary glycemic index and glycemic load and risk of colorectal cancer: results
from the EPIC-Italy study. Int J Cancer 2015;136:2923-31.
101. Sieri S, Agnoli C, Pala V, Grioni S, Brighenti F, et al. Dietary glycemic index, glycemic load, and cancer risk: results from the EPIC-
Italy study. Sci Rep 2017;7:9757.
102. Abe H, Aida Y, Ishiguro H, Yoshizawa K, Miyazaki T, et al. Alcohol, postprandial plasma glucose, and prognosis of hepatocellular car-
cinoma. World J Gastroenterol 2013;19:78-85.
103. Keum N, Yuan C, Nishihara R, Zoltick E, Hamada T, et al. Dietary glycemic and insulin scores and colorectal cancer survival by tumor
molecular biomarkers. Int J Cancer 2017;140:2648-56.
104. Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, et al. Associations of fats and carbohydrate intake with cardiovascular disease
and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet 2017;390:2050-62.
105. Augustin LS, Kendall CW, Jenkins DJ, Willett WC, Astrup A, et al. Glycemic index, glycemic load and glycemic response: an in-
ternational scientific consensus summit from the international carbohydrate quality consortium (ICQC). Nutr Metab Cardiovasc Dis
2015;25:795-815.
106. Augustin LS, Libra M, Crispo A, Grimaldi M, De Laurentiis M, et al. Low glycemic index diet, exercise and vitamin D to reduce breast
cancer recurrence (DEDiCa): design of a clinical trial. BMC Cancer 2017;17:69.
107. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a
prospective study of 251 patients. Hepatology 1995;21:650-5.
108. De Vos Irvine H, Goldberg D, Hole DJ, McMenamin J. Trends in primary liver cancer. Lancet 1998;351:215-6.
109. Kirkegård J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis.
Am J Gastroenterol 2017;112:1366-72.
110. Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF. Crohn’s disease and cancer. N Engl J Med 1973;289:1099-103.
111. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, et al. Overexpression of interleukin-1β induces gastric inflammation and cancer and
mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008;14:408-19.
112. Correa P, Houghton J. Carcinogenesis of helicobacter pylori. Gastroenterology 2007;133:659-72.
113. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7.
114. Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol 2016;12:15-28.
115. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107.
116. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011;11:738-49.
117. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in
human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
118. Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose tissue remodeling: its role in energy metabolism and metabolic disorders. Front
Endocrinol (Lausanne) 2016;7:30.
119. Rutkowski JM, Stern JH, Scherer PE. The cell biology of fat expansion. J Cell Biol 2015;208:501-12.
120. Montane J, Cadavez L, Novials A. Stress and the inflammatory process: a major cause of pancreatic cell death in type 2 diabetes.
Diabetes Metab Syndr Obes 2014;7:25-34.
121. Wang W, Guo Y, Liao Z, Zou DW, Jin ZD, et al. Occurrence of and risk factors for diabetes mellitus in Chinese patients with chronic
pancreatitis. Pancreas 2011;40:206-12.
122. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, et al. Prevalence of diabetes mellitus secondary to pancreatic diseases (type
3c). Diabetes Metab Res Rev 2012;28:338-42.
123. Bhattacharyya S, Marinic TE, Krukovets I, Hoppe G, Stenina OI. Cell type-specific post-transcriptional regulation of production of the
potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose. J Biol Chem 2008;283:5699-707.
124. Bhattacharyya S, Sul K, Krukovets I, Nestor C, Li J, et al. Novel tissue-specific mechanism of regulation of angiogenesis and cancer
growth in response to hyperglycemia. J Am Heart Assoc 2012;1:e005967.
125. Krukovets I, Legerski M, Sul P, Stenina-Adognravi O. Inhibition of hyperglycemia-induced angiogenesis and breast cancer tumor
growth by systemic injection of microRNA-467 antagonist. FASEB J 2015;29:3726-36.
126. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, et al. Signals leading to apoptosis-dependent inhibition of
neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
127. Lawler JW, Slayter HS, Coligan JE. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets.
J Biol Chem 1978;253:8609-16.
128. Liu P, Wang Y, Li YH, Yang C, Zhou YL, et al. Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospon-
din-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res 2003;27:701-8.
129. Xu M, Kumar D, Stass SA, Mixson AJ. Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in
vivo. Mol Genet Metab 1998;63:103-9.
130. Chan LY, Craik DJ, Daly NL. Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich
frameworks to inhibit endothelial cell migration. Biosci Rep 2015; doi: 10.1042/BSR20150210.